Manufacturing Investor Relations and Capex Sequencing Adviser

The mandate

The committee's standing question is how to explain a manufacturing investment sequence credibly when some benefits depend on operating changes that are not yet proven. The adviser will connect capital choices with the financial evidence behind investor narratives. This is not an investor-roadshow mandate or a request to make every project appear strategically indispensable.

Three days monthly cover capital-case interrogation, review of the supporting investor evidence and the finance committee meeting. Attendance is included. Ad-hoc requests receive acknowledgement within two working days and an analytical response within four where source material is supplied; preparing an entire results cycle is outside the reserved retainer capacity.

The six-month term starts on 19 October 2026. The committee chair decides renewal after reviewing the usefulness of the challenge and the independence of the adviser. Advice carries no line authority, and executive responsibility remains with internal leaders. The CFO controls disclosures, while manufacturing and investment owners retain approval and execution signatures.

The sponsor provides capital cases, benefit tracking, funding scenarios and approved investor-information definitions. The adviser should press for a distinction between installed capacity, operationally usable capacity and financially realised benefit. Where a capital narrative relies on the same growth assumption across multiple projects, that dependence must be visible rather than hidden in individually persuasive papers.

Concurrent non-competing advisory work is allowed. A relationship with a competing manufacturer, investor seeking privileged information or supplier whose proposal is under review may create a conflict and requires disclosure. Securities placement, formal valuation opinions and plant delivery management are excluded. The committee is buying experienced challenge of capital and evidence, not reputational cover for a predetermined investment sequence.

What you will own

• Test the capital sequence for shared demand, capacity and funding assumptions, pressing sponsors to show whether individually plausible cases become fragile when considered together.
• Challenge the bridge from installed assets to realised financial benefit, advising which operational milestones should precede a stronger investor claim.
• Shape downside capital options that preserve flexibility, identifying what expenditure can be staged without creating disproportionate contractual or operating penalties.
• Examine investor evidence for consistency with approved finance definitions, flagging where a planning scenario has been described as a committed result.
• Press project sponsors to retain measurable benefit ownership after approval, so capital deployment is not treated as complete merely because the asset is commissioned.
• Review funding explanations alongside the investment sequence, identifying whether timing changes create liquidity or covenant exposure absent from the original paper.
• Record independent advice and the evidence needed for reconsideration, leaving disclosure approval and all binding capital decisions with authorised executives.

Candidate qualifications

• Demonstrate senior corporate-finance or treasury experience in manufacturing, with a concrete example connecting investment sequence and investor evidence. Explain the claim challenged, the operating dependency investigated and how the financial explanation changed.
• Show competence in examining capital benefits rather than only financing cost. Candidates should describe a project whose installed capacity did not immediately produce the expected contribution and how the relevant evidence was brought into the investment review.
• Provide a funding or capital scenario where common assumptions across projects created concentration risk. Explain how you made that dependence visible and advised a staged or alternative approach without claiming executive approval authority.
• Evidence experience handling authorised investor information with clear disclosure boundaries. Describe an unpublished or judgemental measure you refused to endorse prematurely and the source reconciliation required before it could be used.
• Be able to sustain three reserved days monthly and disclose competing manufacturing, supplier or investor relationships. Show how confidentiality and recusal worked in practice, and how advice remained independent when a sponsor sought public endorsement of a preferred project. Explain how an investor measure remained linked to approved source evidence after a project sequence changed. Candidates should show the revised bridge, the disclosure owner consulted and the point at which a scenario could no longer support the original statement.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 7 October 2026. Mandate reference PCT-ADV-2026-IND-06.